STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Data add to expectations that the drug will be one of Lilly’s greatest growth
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 28 06:45 ETSource: STAT
From the source
Read at statnews.comSTAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
